BCG Vaccine Lowers Incidence of Alzheimer’s in Bladder Cancer Patients, Study Finds

BCG Vaccine Lowers Incidence of Alzheimer’s in Bladder Cancer Patients, Study Finds
The Bacillus Calmette-Guérin (BCG) vaccine, which provides protection against tuberculosis, can reduce the incidence of Alzheimer’s disease in patients with bladder cancer — and potentially provide new avenues to explore this effect in the general population, according to a recent study. The study, "Bacillus Calmette-Guérin (BCG) therapy lowers the incidence of Alzheimer’s disease in bladder cancer patients," was published in the journal PLOS One. In addition to providing protection against tuberculosis, the BCG vaccine has also been used as a preventive treatment to reduce the recurrence of certain forms of bladder cancer. Although its exact mechanism of action is unknown, scientists believe BCG’s anticancer activity is linked to its ability to modulate the body’s immune system. The immune system is known to play a major role in Alzheimer’s. Recent studies have proposed that the BCG vaccine may lower the prevalence of Alzheimer’s among the elderly by altering their immune system. This hypothesis was put forward based on past data showing an inverse relationship between BCG vaccination and the prevalence of Alzheimer’s or dementia. "There's data reaching back to the 1960s that shows that countries treating bladder cancer patients with the BCG v
Subscribe or to access all post and page content.